Á. Gómez-Ferrer

620 total citations
67 papers, 406 citations indexed

About

Á. Gómez-Ferrer is a scholar working on Pulmonary and Respiratory Medicine, Rheumatology and Surgery. According to data from OpenAlex, Á. Gómez-Ferrer has authored 67 papers receiving a total of 406 indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Pulmonary and Respiratory Medicine, 25 papers in Rheumatology and 18 papers in Surgery. Recurrent topics in Á. Gómez-Ferrer's work include Prostate Cancer Diagnosis and Treatment (43 papers), Prostate Cancer Treatment and Research (40 papers) and Urologic and reproductive health conditions (17 papers). Á. Gómez-Ferrer is often cited by papers focused on Prostate Cancer Diagnosis and Treatment (43 papers), Prostate Cancer Treatment and Research (40 papers) and Urologic and reproductive health conditions (17 papers). Á. Gómez-Ferrer collaborates with scholars based in Spain, Italy and France. Á. Gómez-Ferrer's co-authors include J. Rubio‐Briones, José L. Domínguez-Escrig, I. Iborra, E. Solsona, A. Collado, M. Backhaus, J. Casanova, J.V. Ricós, J.L. Monrós and R. Dumont and has published in prestigious journals such as Journal of Clinical Oncology, Urology and BMC Cancer.

In The Last Decade

Á. Gómez-Ferrer

63 papers receiving 399 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Á. Gómez-Ferrer Spain 11 318 189 121 95 38 67 406
Vito Lacetera Italy 11 177 0.6× 118 0.6× 87 0.7× 79 0.8× 53 1.4× 38 324
Khaled Ajib Canada 10 185 0.6× 63 0.3× 90 0.7× 68 0.7× 53 1.4× 31 277
Lukas Hohenhorst Germany 10 202 0.6× 84 0.4× 134 1.1× 120 1.3× 16 0.4× 43 314
Patrick‐Julien Treacy United States 10 288 0.9× 128 0.7× 55 0.5× 121 1.3× 51 1.3× 29 410
Mischel G. Neill Canada 11 338 1.1× 146 0.8× 181 1.5× 112 1.2× 49 1.3× 20 429
D. van den Ouden Netherlands 8 341 1.1× 328 1.7× 199 1.6× 271 2.9× 25 0.7× 12 554
Christopher L. Amling United States 6 330 1.0× 125 0.7× 28 0.2× 66 0.7× 59 1.6× 7 360
Jin Kyu Oh South Korea 11 176 0.6× 109 0.6× 179 1.5× 38 0.4× 19 0.5× 29 332
W. Horninger Austria 6 334 1.1× 137 0.7× 136 1.1× 130 1.4× 118 3.1× 10 460
Nicholas T. Karanikolas United States 6 219 0.7× 82 0.4× 57 0.5× 83 0.9× 49 1.3× 22 273

Countries citing papers authored by Á. Gómez-Ferrer

Since Specialization
Citations

This map shows the geographic impact of Á. Gómez-Ferrer's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Á. Gómez-Ferrer with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Á. Gómez-Ferrer more than expected).

Fields of papers citing papers by Á. Gómez-Ferrer

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Á. Gómez-Ferrer. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Á. Gómez-Ferrer. The network helps show where Á. Gómez-Ferrer may publish in the future.

Co-authorship network of co-authors of Á. Gómez-Ferrer

This figure shows the co-authorship network connecting the top 25 collaborators of Á. Gómez-Ferrer. A scholar is included among the top collaborators of Á. Gómez-Ferrer based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Á. Gómez-Ferrer. Á. Gómez-Ferrer is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Martínez-Corral, María Elena, et al.. (2025). PSA kinetics and predictors of PSA response in metastatic hormone-sensitive prostate cancer treated with androgen receptor signaling inhibitors. Urologic Oncology Seminars and Original Investigations. 43(9). 527.e9–527.e15.
2.
Tombal, Bertrand, F. Gómez-Veiga, Á. Gómez-Ferrer, et al.. (2024). A Phase 2 Randomized Open-label Study of Oral Darolutamide Monotherapy Versus Androgen Deprivation Therapy in Men with Hormone-sensitive Prostate Cancer (EORTC-GUCG 1532). European Urology Oncology. 7(5). 1051–1060. 5 indexed citations
3.
Borque‐Fernando, Ángel, Josep María Gaya, Luis Esteban, et al.. (2023). Epidemiology, Diagnosis and Management of Penile Cancer: Results from the Spanish National Registry of Penile Cancer. Cancers. 15(3). 616–616. 8 indexed citations
4.
Carles, Joan, R.A. Medina López, Javier Puente, et al.. (2023). Darolutamide in Spanish patients with nonmetastatic castration-resistant prostate cancer: ARAMIS subgroup analysis. Future Oncology. 19(12). 819–828. 1 indexed citations
5.
Marenco, José Luis, Á. Gómez-Ferrer, Alessandro Zucchi, et al.. (2023). Sentinel Lymph Node Biopsy in Prostate Cancer: An Overview of Diagnostic Performance, Oncological Outcomes, Safety, and Feasibility. Diagnostics. 13(15). 2543–2543. 5 indexed citations
6.
Claps, Francesco, et al.. (2023). Personalised indocyanine‐guided lymphadenectomy for prostate cancer: a randomised clinical trial. British Journal of Urology. 132(5). 591–599. 5 indexed citations
7.
Rubio‐Briones, J., Ángel Borque‐Fernando, Luis Esteban, et al.. (2020). Validation of a 2‐gene mRNA urine test for the detection of ≥GG2 prostate cancer in an opportunistic screening population. The Prostate. 80(6). 500–507. 8 indexed citations
8.
Jiménez, José L., Francesco Claps, Á. Gómez-Ferrer, et al.. (2020). Rebiopsy rate after transperineal or transrectal prostate biopsy. Prostate International. 9(2). 78–81. 12 indexed citations
9.
Rubio‐Briones, J., M. Backhaus, Á. Gómez-Ferrer, et al.. (2018). Resultados oncológicos a largo plazo del tratamiento cáncer de próstata de alto riesgo mediante prostatectomía radical en un hospital oncológico. Actas Urológicas Españolas. 42(8). 507–515. 2 indexed citations
10.
Rubio‐Briones, J., Ángel Borque‐Fernando, Luis Esteban, et al.. (2015). Optimizing the clinical utility of PCA3 to diagnose prostate cancer in initial prostate biopsy. BMC Cancer. 15(1). 633–633. 13 indexed citations
11.
Rubio‐Briones, J., I. Iborra, Ana Calatrava, et al.. (2014). Información obligatoria que debe conocer un paciente con cáncer de próstata candidato a vigilancia activa. Actas Urológicas Españolas. 38(9). 559–565. 20 indexed citations
12.
Domínguez-Escrig, José L., et al.. (2013). AdVance/AdVance XP Transobturator Male Slings: Preoperative Degree of Incontinence as Predictor of Surgical Outcome. Urology. 81(5). 1034–1039. 75 indexed citations
13.
Backhaus, M., J. Rubio‐Briones, Á. Gómez-Ferrer, et al.. (2013). El margen quirúrgico es el factor pronóstico de mayor relevancia en los pacientes con cáncer de próstata que infiltra las vesículas seminales. Actas Urológicas Españolas. 37(9). 538–543. 2 indexed citations
14.
Rubio‐Briones, J., et al.. (2012). Urodynamic changes following salvage radiotherapy for recurrent prostate cancer after radical prostatectomy. 1 indexed citations
15.
Gómez-Ferrer, Á., J. Rubio‐Briones, A. Collado, et al.. (2011). Reconstrucción del glande con injerto cutáneo libre según técnica de Bracka. Actas Urológicas Españolas. 35(3). 180–183. 5 indexed citations
16.
Rubio‐Briones, J., Ana Calatrava, Antonio Fernández‐Serra, et al.. (2011). Expresión inmunohistoquímica de la densidad microvascular y de la anhidrasa carbónica IX en carcinoma renal. Relación con el tipo histológico y con la progresión tumoral. Actas Urológicas Españolas. 35(2). 80–86. 3 indexed citations
17.
Gómez-Ferrer, Á., et al.. (2011). Análisis de imagen asistido por ordenador en ecografía transrectal de próstata. Actas Urológicas Españolas. 35(7). 404–413. 1 indexed citations
18.
Rubio‐Briones, J., Antonio Fernández‐Serra, Luis Rubio, et al.. (2011). Resultados del uso expandido del PCA3 score en una población española con sospecha de cáncer de próstata. Actas Urológicas Españolas. 35(10). 589–596. 21 indexed citations
19.
Collado, Argimiro, et al.. (2009). ¿Qué pacientes con incontinencia de esfuerzo tras prostatectomía radical se benefician de la indicación de invance®?. Archivos Españoles de Urología. 62(10). 851–9. 9 indexed citations
20.
Gómez-Ferrer, Á., et al.. (2002). Tumores retroperitoneales primarios: nuestra casuistica. Actas Urológicas Españolas. 26(1). 29–35. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vito Lacetera Breakdown of academic impact, for papers by Khaled Ajib Breakdown of academic impact, for papers by Lukas Hohenhorst Breakdown of academic impact, for papers by Patrick‐Julien Treacy Breakdown of academic impact, for papers by Mischel G. Neill Breakdown of academic impact, for papers by D. van den Ouden Breakdown of academic impact, for papers by Christopher L. Amling Breakdown of academic impact, for papers by Jin Kyu Oh Breakdown of academic impact, for papers by W. Horninger Breakdown of academic impact, for papers by Nicholas T. Karanikolas
Rankless by CCL
2026